Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Dickerson

Showing results (281-290 of 300) with videos related to

Pageof 30
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2011
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's diseaseCarrie K Jones, Michael Bubser, Analisa D Thompson, et al.
JACC. Basic to Translational Science|December 14, 2023
Development of a Peripherally Restricted 5-HT<sub>2B</sub> Partial Agonist for Treatment of Pulmonary Arterial HypertensionMichael S Valentine, Aaron M Bender, Sheila Shay, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 26, 2015
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse ModelA Ghoshal, J M Rook, J W Dickerson, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
ACS Medicinal Chemistry Letters|August 20, 2021
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M<sub>4</sub> Muscarinic Acetylcholine Receptor AntagonistMatthew Spock, Trever R Carter, Katrina A Bollinger, et al.
ACS Chemical Neuroscience|August 28, 2024
Discovery of VU6007496: Challenges in the Development of an M<sub>1</sub> Positive Allosteric Modulator Backup CandidateJulie L Engers, Katrina A Bollinger, Rory A Capstick, et al.
ACS Chemical Neuroscience|March 25, 2025
Application of Deuterium in an M<sub>1</sub> Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422Julie L Engers, Jinming Li, Changho Han, et al.
ACS Chemical Neuroscience|February 5, 2025
Further Optimization of the mGlu<sub>1</sub> PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685Carson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Chemical Neuroscience|November 26, 2025
Discovery of VU6052254: A Novel, Potent M<sub>1</sub> Positive Allosteric ModulatorJulie L Engers, Joseph D Bungard, Christopher C Presley, et al.
Pageof 30

Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2011
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's diseaseCarrie K Jones, Michael Bubser, Analisa D Thompson, et al.
JACC. Basic to Translational Science|December 14, 2023
Development of a Peripherally Restricted 5-HT<sub>2B</sub> Partial Agonist for Treatment of Pulmonary Arterial HypertensionMichael S Valentine, Aaron M Bender, Sheila Shay, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 26, 2015
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse ModelA Ghoshal, J M Rook, J W Dickerson, et al.
ACS Chemical Neuroscience|April 28, 2018
A Novel M<sub>1</sub> PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic ToxicityJerri M Rook, Jeanette L Bertron, Hyekyung P Cho, et al.
ACS Chemical Neuroscience|December 22, 2016
Diverse Effects on M<sub>1</sub> Signaling and Adverse Effect Liability within a Series of M<sub>1</sub> Ago-PAMsJerri M Rook, Masahito Abe, Hyekyung P Cho, et al.
ACS Medicinal Chemistry Letters|August 20, 2021
Discovery of VU6028418: A Highly Selective and Orally Bioavailable M<sub>4</sub> Muscarinic Acetylcholine Receptor AntagonistMatthew Spock, Trever R Carter, Katrina A Bollinger, et al.
ACS Chemical Neuroscience|August 28, 2024
Discovery of VU6007496: Challenges in the Development of an M<sub>1</sub> Positive Allosteric Modulator Backup CandidateJulie L Engers, Katrina A Bollinger, Rory A Capstick, et al.
ACS Chemical Neuroscience|March 25, 2025
Application of Deuterium in an M<sub>1</sub> Positive Allosteric Modulator Back-Up Program: The Discovery of VU6045422Julie L Engers, Jinming Li, Changho Han, et al.
ACS Chemical Neuroscience|February 5, 2025
Further Optimization of the mGlu<sub>1</sub> PAM VU6024578/BI02982816: Discovery and Characterization of VU6033685Carson W Reed, Jacob F Kalbfleisch, Jeremy A Turkett, et al.
ACS Chemical Neuroscience|November 26, 2025
Discovery of VU6052254: A Novel, Potent M<sub>1</sub> Positive Allosteric ModulatorJulie L Engers, Joseph D Bungard, Christopher C Presley, et al.
Pageof 30